Shire Fosrenol Clears FDA For ESRD; Kidney Stone Studies May Be Next
Executive Summary
Shire may be eying a kidney stone indication for Fosrenol following FDA clearance of the end-stage renal disease therapy
You may also be interested in...
With Renvela, Genzyme Wants To Grow Market, But Not Necessarily Share
Genzyme will manage the launch of Renvela (sevelamer carbonate) in the first quarter of 2008 to grow the brand and the market, Renal Division President John Butler told analysts during the company's Oct. 24 earnings call
With Renvela, Genzyme Wants To Grow Market, But Not Necessarily Share
Genzyme will manage the launch of Renvela (sevelamer carbonate) in the first quarter of 2008 to grow the brand and the market, Renal Division President John Butler told analysts during the company's Oct. 24 earnings call
Genzyme Renagel Growth To Come From Medicare Rx, Kidney Disease Use
Genzyme expects results from a Phase IV Renagel outcomes study to bolster the phosphate binder's long-term growth prospects, Renal Division General Manager John Butler told investors Feb. 19